Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract

Odyssey Health, Inc.

• NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
• NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.
• Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.
• Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.